Compare CRK & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRK | OGN |
|---|---|---|
| Founded | 1983 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.6B |
| IPO Year | 1995 | 2020 |
| Metric | CRK | OGN |
|---|---|---|
| Price | $14.94 | $13.77 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 4 |
| Target Price | ★ $15.30 | $10.33 |
| AVG Volume (30 Days) | ★ 2.4M | 2.0M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | ★ 288.16 | N/A |
| EPS | 0.40 | ★ 0.95 |
| Revenue | $555,231,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.07 |
| P/E Ratio | $37.15 | ★ $14.46 |
| Revenue Growth | ★ 32.11 | N/A |
| 52 Week Low | $12.12 | $5.69 |
| 52 Week High | $28.10 | $13.83 |
| Indicator | CRK | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 63.77 | 56.17 |
| Support Level | $12.49 | $13.72 |
| Resistance Level | $15.22 | $13.78 |
| Average True Range (ATR) | 0.55 | 0.04 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 96.91 | 43.48 |
Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. The company's oil and gas operations are concentrated in Louisiana and Texas.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.